Journal of Bone and Mineral Research

Cover image for Vol. 31 Issue 7

Edited By: Juliet E Compston

Impact Factor: 5.622

ISI Journal Citation Reports © Ranking: 2015: 15/131 (Endocrinology & Metabolism)

Online ISSN: 1523-4681

News


JBMR in the News:Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures

Published on 04/05/13 by ASBMR


The goal of this MR-imaging study was to quantify vertebral bone marrow fat content and composition in diabetic and non-diabetic postmenopausal women with fragility fractures and to compare them with non-fracture controls with and without type-2 diabetes mellitus. Sixty-nine postmenopausal women (mean age 63 ± 5 years) were recruited. Thirty-six patients (47.8%) had spinal and/or peripheral fragility fractures. Seventeen fracture patients were diabetic. Thirty-three women (52.2%) were non-fracture controls. Sixteen women were diabetic non-fracture controls. To quantify vertebral bone marrow fat content and composition, patients underwent MR-spectroscopy (MRS) of the lumbar spine at 3 Tesla. Bone mineral density (BMD) was determined by dual-energy X-Ray-absorptiometry (DXA) of the hip and lumbar spine (LS) and quantitative computed tomography (QCT) of the LS. To evaluate associations of vertebral marrow fat content and composition with spinal and/or peripheral fragility fractures and diabetes, we used linear regression models adjusted for age, race, and spine vBMD by QCT. At the LS, non-diabetic and diabetic fracture patients had lower vBMD than controls and diabetics without fractures (p = 0.018; p = 0.005). However, aBMD by DXA did not differ between fracture and non-fracture patients. After adjustment for age, race, and spinal vBMD, the prevalence of fragility fractures was associated with −1.7% lower unsaturation levels (confidence interval [CI] −2.8% to −0.5%, p = 0.005) and +2.9% higher saturation levels (CI 0.5% to 5.3%, p = 0.017). Diabetes was associated with −1.3% (CI −2.3% to −0.2%, p = 0.018) lower unsaturation and +3.3% (CI 1.1% to 5.4%. p = 0.004) higher saturation levels. Diabetics with fractures had the lowest marrow unsaturation and highest saturation. There were no associations of marrow fat content with diabetes or fracture. Our results suggest that altered bone marrow fat composition is linked with fragility fractures and diabetes. MRS of spinal bone marrow fat may therefore serve as a novel tool for BMD-independent fracture risk assessment. © 2013 American Society for Bone and Mineral Research.
 

Click Here to Read the Story at MDLinx
Click Here to Read the Article

Click Here to Read More News

 

JBMR in the News: As seen in the San Diego Reader and the LA Times

Published on Mar 26, 2013 ASBMR/p>

Fluoride From Tea Can Cause Bone and Tooth Damage

A Detroit woman’s 17-year-long extreme tea overdose caused her to lose all her teeth and experience debilitating bone pain. She drank a pitcher of tea made from over 100 tea bags every day for 17 years. The culprit: Fluoride.

Click here and here for research on this topic from the JBMR.

Click Here to Read the Story in the LA Times

Click Here to Read the Story in the San Diego Reader

Click Here to Read More News


JBMR in the News: Bone Loss Rx Didn't Lower Cancer Risk

Published on Mar 25, 2013 ASBMR

Colorectal cancer risk reduction not associated with oral bisphosphonate use

(dailyRx News) It’s always exciting when researchers find a new benefit for an existing medication. One type of medicine that treats bone loss has been shown to have anti-cancer properties.

Medications that treat bone loss are called bisphosphonates. A new study has concluded that the use of oral bisphosphonates did not lower the risk of colorectal cancer... Click Here to Read the Story at dailyRX

Click Here to Read the Abstract

Click Here to Read More News

 

JBMR in the News: MDLinx

Published on Mar 25, 2013 ASBMR


This week the JBMR received news coverage for multiple recently published articles.


Oral bisphosphonate use and colorectal cancer incidence in the Womens Health Initiative

Click Here to Read the Story at MDLinx
 




Monocyte chemoattractant protein-1 is a mediator of the anabolic action of parathyroid hormone on bone

Click Here to Read the Story at MDLinx
 



Multisite quantitative ultrasound for the prediction of fractures over five years of follow-up: The Canadian Multicentre Osteoporosis Study
 

Click Here to Read the Story at MDLinx
 



Fracture risk and height: An association partly accounted for by cortical porosity of relatively thinner cortices

Click Here to Read the Story at MDLinx


p130Cas plays important roles in osteoclastic bone resorption

Click Here to Read the Story at MDLinx



Chd4 and associated proteins function as corepressors of Sox9 expression during BMP-2-induced chondrogenesis

Click Here to Read the Story at MDLinx
 


RANKL subcellular trafficking and regulatory mechanisms in osteocytes


Click Here to Read the Story at MDLinx



Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1

Click Here to Read the Story at MDLinx



Architecture of the Osteocyte Network Correlates with Bone Material Quality

Click Here to Read the Story at MDLinx



Evidence for a genetic link between bone and vascular measures in African ancestry families
 


Click Here to Read the Story at MDLinx

 


Click Here to Read More News
 

 

 

JBMR in the News: As seen on Men's Health on NBCNEWS.com

Published on Mar 22, 2013 ASBMR

Men get osteoporosis, too -- but they probably don't know it

When a 77-year-old tennis player fell during a match and fractured his hip while on vacation in Key Largo, Fla., he became part of a little known, serious and growing problem among older men.

Three years after the accident, E. Neil Moore of suburban Philadelphia, not only can’t play tennis or run -- he feels too fragile to visit Florida on his own. When he broke his hip, Moore, now 80, was suffering from osteoporosis, a disease of fragile bones usually associated with women. Even though he's an expert in the electrophysiology of the heart who taught at the University of Pennsylvania’s Perelman School of Medicine for 40 years, wasn’t aware he had the condition. Click Here to Read the Story on NBCNEWS.com

Click Here to Read the Paper

and click HERE for an eCompendium on male osteoporosis from the JBMR.

An eCompendium is an online collection of previously published JBMR content organized around a common theme.


Click Here to Read More News

 

JBMR in the News: Sclerostin and bone strength in women in their 10th decade of life

Published on Mar 20, 2013 ASBMR

Thorson S et al. – Sclerostin is a potent inhibitor of bone formation but has been shown to correlate positively with areal bone mineral density (aBMD). Little is known about its relationship to parameters of bone strength and volumentric BMD (vBMD) as measured by peripheral quantitative computed tomography (pQCT). The results suggest paradoxical associations between circulating sclerostin and bone size, density and strength.

Click Here to Read the Story at MDLinx

Click Here to Read the Abstract

Click Here to Read More News

 

JBMR in the News: Eye Risk Low with Bisphosphonates from Arthritis Today

Published on Mar 15, 2013 ASBMR

People taking bisphosphonates, used to treat osteoporosis, have only a slightly higher risk of developing an inflammatory eye reaction, such as uveitis or conjunctivitis, than those taking other kinds of osteoporosis drugs, according to a new study out of Denmark. Having an underlying rheumatic condition, like rheumatoid arthritis (RA), or a lung disease raises that risk, but it still remains small. The study appears in the March issue of the Journal of Bone and Mineral Research.

Click Here to Read the Story at Arthritis Today
Click Here to Read the Abstract
Click Here to Read More News

 

JBMR in the News: Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?

Published on Mar 15, 2013 ASBMR

Zoledronic acid is used to treat bone disease in both multiple myeloma (MM) and breast cancer patients (pts) with bone metastasis (BC). However, bones of MM and BC pts show a difference in retention of the bisphosphonate used for bone scintigraphy. Therefore we hypothesized that disease-specific factors may differently influence Zol retention in MM and BC pts. We tested this hypothesis in an investigator initiated phase II clinical trial where we compared the whole body retention (WBrt) of Zol in a cohort of 30 multiple myeloma (MM) and 30 breast cancer (BC) (20 Zol naive and 40 with ≥6 previous administrations). On average, 62% of the administered Zol was retained in the skeleton of both MM and BC pts and independently of the number of treatments. WBrt of Zol did not correlate with CTX levels, but linear regression analyses showed correlation with bALP levels in BC (p=0.001), but rather with CTX/bALP in Zol naive MM pts (p=0.012). Especially in BC pts WBrt correlated with age (p=0.014) independently of kidney function. In MM pts WBrt was found to primarily correlate with the extent of bone disease (p=0.028). Multivariate linear regression analyses of the entire cohort pointed out that WBrt of Zol was best predicted by age (p<0.000), osseous lesions (p<0.001) and the preceding Zol dosing (p<0.005)(r(2) =0.97). Comparing bone scintigrams with CT/X-ray images showed a poor correlation between sites of active bone disease and binding of scintigraphy bisphosphonate in 36% of MM pts and in 13% of BC pts. We conclude that WBrt of Zol is primarily determined by non-disease related factors, but that there may be differences in retention or drug delivery at individual sites of bone disease between MM and BC pts. In order to find the optimal dosing of Zol these observations should be taken into account.

Click Here to Read the Story at DocGuide

Click Here to Read the Abstract

Click Here to Read More News

 

JBMR in the News: MDLinx

Published on Mar 12, 2013 ASBMR

This week the JBMR received news coverage for multiple recently published articles.

A distal forearm fracture in childhood is associated with an increased risk for future fragility fractures in adult men, but not women

Click Here to Read the Story at MDLinx



C-reactive protein, bone strength, and 9-year fracture risk: Data from the study of womens health across the nation (SWAN)
 

Click Here to Read the Story at MDLinx



A semi-mechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans

 

Click Here to Read the Story at MDLinx

Click Here to Read More News

 

JBMR in the News: DocGuide.com

Published on Mar 8, 2013 ASBMR

This week the JBMR received news coverage for multiple recently published articles.

BMD changes and predictors of increased bone loss in postmenopausal women following a 5-year course of alendronate

Click Here to View on DocGuide.com


Do gamma delta T-cells predict osteonecrosis of the jaw?


Click Here to View on DocGuide.com


Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation
 
Click Here to View on DocGuide.com


Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis


Click Here to View on DocGuide.com


Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy

Click Here to View on DocGuide.com


Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan

Click Here to View on DocGuide.com


Acute effect of calcium citrate on serum calcium and cardiovascular function

Click Here to View on DocGuide.com


Meta-analysis of vertebral augmentation compared with conservative treatment for osteoporotic spinal fractures

Click Here to View on DocGuide.com


Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures

Click Here to View on DocGuide.com

 

Click Here to Read More News
 


JBMR in the News: Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor

Published on Mar 8, 2013 ASBMR

States of growth hormone (GH) resistance, such those observed in Laron's dwarf patients, are characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired glucose tolerance, and impaired skeletal acquisition.

Click Here to Read the Story at SciBite

Click Here to Read the Story at ScienceAlerts.com
Click Here to Read the Abstract
Click Here to Read More News
 

JBMR in the News: Plasminogen plays a crucial role in bone repair

Published on Mar 8, 2013 ASBMR

The further development in research of bone regeneration is necessary to meet the clinical demand for bone reconstruction. Plasminogen is a critical factor of the tissue fibrinolytic system, which mediates tissue repair in the skin and liver. However, the role of the fibrinolytic system in bone regeneration remains unknown.

Click Here to Read the Story at ScienceAlerts.com

Click Here to Read the Abstract

Click Here to Read More News

 

JBMR in the News: Bone blood flow and metabolism in humans: Effect of muscular exercise and other physiological perturbations

Published on Mar 4, 2013 ASBMR

Heinonen I et al. – Human bone blood flow and metabolism during physical exercise remains poorly characterised. In the present study the authors measured femoral bone blood flow and glucose uptake in young healthy subjects by positron emission tomography in three separate protocols. resting femoral bone blood flow increases by physical exercise, but appears to level off with increasing exercise intensities. Moreover, while moderate systemic hypoxia does not change bone blood flow at rest or during exercise, intra–arterially administered adenosine during resting conditions is capable of enhancing bone blood flow in humans markedly. Finally, also bone glucose uptake increases substantially in response to exercise

Click Here to Read the Story at MDLinx

Click Here to Read the Abstract

Click Here to Read More News

JBMR in the News: Degree of biological apatite c-axis orientation rather than bone mineral density controls mechanical function in bone regenerated using rBMP-2

Published on Mar 4, 2013 ASBMR

Ishimoto T et al. – The aim of the present study was to assess the bone regeneration process in defects introduced into rabbit long bones, which were regenerated with controlled release of recombinant bone morphogenetic protein–2 (rBMP–2). Preferential BAp c–axis orientation is a strong determinant and predictor of the mechanical function of tissue–engineered bone. Therefore, analysis of BAp preferential c–axis orientation in addition to measurement of BMD is crucial in assessment of bone mechanical function.

Click Here to Read the Story at MDLinx
Click Here to Read the Abstract
Click Here to Read More News

JBMR in the News: Enzyme may benefit rare soft-bone disease

Published on Mar 4, 2013 ASBMR

People with a heritable form of rickets lack an enzyme that allows bones and teeth to harden properly, researchers find. Diagnosed in toddlers, X-linked hypophosphatemia (XLH) is the most common form of heritable rickets, in which soft bones bend and deform, and tooth abscesses develop because infections penetrate soft teeth that are not properly calcified.

Click Here to Read the Story at Futurity
Click Here to Read the Abstract
Click Here to Read More News

JBMR in the News: Changes in the epigenetic status of the SOX-9 promoter in human osteoarthritic cartilage

Published on Feb 25, 2013 ASBMR

Kim KI et al. – It is largely unknown whether osteoarthritis (OA) is associated with alterations in the epigenetic status of anabolic factors. The findings suggest that hip OA is associated with a change in the epigenetic status of SOX–9 promoter including increased DNA methylation and altered histone modification.

Click Here to Read the Story at MDLinx

Click Here to Read the Abstract

Click Here to Read More News


JBMR in the News: 18F-fluoride PET as a non-invasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomised, controlled clinical study

Published on Feb 25, 2013 ASBMR

Frost ML et al. – The aim of this study was to determine if 18F–PET can be used as an early biomarker of treatment efficacy at the hip. Changes in BMD and bone turnover markers were consistent with previous trials of teriparatide. In conclusion, this is the first study demonstrating that 18F–PET can be used as an imaging biomarker for determining treatment efficacy at the hip as early as 12–weeks following initiation of therapy.

Click Here to Read the Story at MDLinx

Click Here to Read the Abstract

Click Here to Read More News
 

 

JBMR in the News: Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

Published on Feb 25, 2013 ASBMR

Glüer CC et al. – Data on treatment of glucocorticoid–induced osteoporosis (GIO) in men are scarce. In this 18–month trial in men with GIO, teriparatide showed larger improvements in spinal BMD, microstructure, and finite element (FE)–derived strength than risedronate

Click Here to Read the Story at MDLinx

Click Here to Read the Abstract

Click Here to Read More News

JBMR in the News: Risk factors for the development of vertebral fractures after percutaneous vertebroplasty

Published on Feb 21, 2013 ASBMR


Martinez–Ferrer A et al. – The authors have recently observed an increased risk for vertebral fractures (VF) in a randomized controlled trial comparing the analgesic effect of vertebroplasty (VP) versus conservative treatment in symptomatic VF. The aim of the present study was to evaluate the risk factors related to the development of VF after VP in these patients. Nearly 30% of patients with osteoporotic VF treated with VP had a new VF after the procedure. Age, especially over 80 years, the presence of inferior disk cement leakage after the procedure, the number of cemented vertebrae and low 25OHD serum levels were related to the development of new VF in these patients; the latter indicating the need to correct vitamin D deficiency prior to performing VP.

Read the story at MDLinx

Read the story at DocGuide

Click here to read the Abstract

 

JBMR in the News: Gains Made Towards Treatment of Rare Bone Disease

Published on Feb 20, 2013 ASBMR

Diagnosed in toddlers, X-linked hypophosphatemia (XLH) is the most common form of heritable rickets, in which soft bones bend and deform, and tooth abscesses develop because infections penetrate soft teeth that are not properly calcified. Researchers at McGill University and the Federal University of Sao Paulo have identified that osteopontin, a major bone and tooth substrate protein, plays a role in XLH. Their discovery may pave the way to effectively treating this rare disease.

Click Here to Read the Story at ScienceDaily
Click Here to Read the Abstract

 

JBMR in the International News

Published on Feb 19, 2013 ASBMR

The JBMR has received international news coverage for two articles published in the March 2013 issue.

 Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia
 

Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus


 

JBMR in the News: Structure and strength of the distal radius in female patients with rheumatoid arthritis: A case-control study

Published on Feb 19, 2013 ASBMR

Zhu TY et al. – The study aims to investigate volumetric bone mineral density (vBMD), bone microstructure and mechanical indices of the distal radius in female patients with rheumatoid arthritis (RA). HR–pQCT provides new insight into inflammation–associated bone fragility in RA. It detects differences in vBMD, bone microstructure and mechanical indices that are not captured by DXA.

Read the Story at MDLinx
Click Here to Read the Abstract

JBMR in the News: In obese postmenopausal women, bone microarchitecture and strength are not commensurate to greater body weight. The OFELY study

Published on Feb 19, 2013 ASBMR

Sornay–Rendu E et al. – Obesity is associated with higher areal bone density (aBMD) but its protective effect on the risk of fracture is controversial. The authors aimed to analyse bone microarchitecture and biomechanical properties in obese (OB) postmenopausal French women compared with normal weight (NW) women.

Read the Story at MDLinx
Click Here to Read the Abstract

JBMR in the News: Quantitative ultrasound of cortical bone in the femoral neck predicts femur strength: Results of a pilot study

Published on Jan 25, 2013 ASBMR

A significant risk of femoral neck (FN) fracture exists for men and women with an areal bone mineral density (aBMD) higher than the osteoporotic range, as measured with dual-energy X-ray absorptiometry (DXA). The results of this study demonstrate that quantitative ultrasound (QUS) can perform a targeted measurement of the FN cortical compartment. Because the method involves mechanical guided waves, the QUS variable is related to the geometric and material properties of the cortical shell (cortical thickness, tissue elasticity, and porosity). This work opens the way to a multimodal QUS assessment of the proximal femur, combining the approach targeting the cortical shell with the existing modality sensitive to the trabecular compartment. In vivo feasibility of the approach has to be confirmed with experimental data in patients.

Read the story at MDLinx

Click here to read the Abstract

 

Video Interview: Editor-in-Chief Juliet Compston Outlines Her Goals for JBMR

Published on Jan 18, 2013 ASBMR

In this ASBMR interview, JBMR Editor-in-Chief Juliet Compston discusses her goals for the Journal, and her personal advice to researchers submitting papers.



JBMR in the News: FRAX with or without BMD predicted fractures in obese, nonobese women

Published on Jan 16, 2013 ASBMR

WHO fracture risk algorithm scores with or without bone mineral density were useful models to predict clinical fractures in obese and nonobese women, according to data published in the Journal of Bone and Mineral Research.

Read story at Healio

Introducing Juliet E. Compston, new Editor-in-Chief of the JBMR

Published on Jan 3, 2013 ASBMR

Juliet E. Compston

ASBMR is pleased to welcome Juliet E. Compston, M.D., of the University of Cambridge School of Clinical Medicine as the fifth Editor-in-Chief of the Journal of Bone and Mineral Research (JBMR), the Society’s official journal and the leading journal in the field. She succeeds Dr. Thomas L. Clemens as the JBMR's Editor-in-Chief on January 1, 2013.

Dr. Compston earned her MB BS degree at The Middlesex University Hospital Medical School and her M.D. at the University of London.  She is the author or co-author of over 300 peer-reviewed papers, 64 book chapters and 9 books.  In addition, Dr. Compston previously served as an Associate Editor of the JBMR, a Senior Associate Editor of the ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, and has served on the editorial boards of Bone, Calcified Tissue International, Osteoporosis International, and the Journal of Clinical Densitometry.  She has extensive experience in scientific society and other leadership positions in the UK, Europe and the US, and has received many honors including the National Osteoporosis Society Kohn Foundation Award (2006), the IBMS John G. Haddad Jr. Award (2009), and the ASBMR Fredric C. Bartter Award (2009).


New Virtual Issue: Raisz-Drezner First Paper Award Winners

Published on Oct 23, 2012 ASBMR

The Editor-in-Chief is pleased to announce a new Virtual Issue highlighting the Raisz-Drezner First Paper Award winners from 2008-2012.

This new virtual issue highlights the ASBMR Raisz-Drezner First Paper Award winners published in the JBMR from 2008-2012. The Award honors first authors of meritorious scientific publications published in the JBMR.

Virtual Issues are thematic or topical collections of JBMR articles. This new Virtual Issue joins those on osteoporosis treatment, basic and clinical review articles published over the past four years in the JBMR, another on parathyroid hormone (PTH), and two more on the 10 most frequently cited JBMR articles from 1986-present and the Top 10 downloads from 2010-2011.


New Virtual Issue: Osteoporosis Treatment

Published on Sep 14, 2012 ASBMR

The Editor-in-Chief is pleased to announce a new Virtual Issue of the JBMR on the topic of osteoporosis treatment.

This new virtual issue is a collection of papers on the topic of osteoporosis treatment and fracture risk assessment, published in the JBMR over the past three years.

Virtual Issues are thematic or topical collections of JBMR articles. This new Virtual Issue joins those on basic and clinical review articles published over the past four years in the JBMR, another on parathyroid hormone (PTH), and two more on the 10 most frequently cited JBMR articles from 1986-present and the Top 10 downloads from 2010-2011.


Juliet E. Compston appointed Editor-in-Chief of the JBMR

Published on Jun 11, 2012 ASBMR

The ASBMR Council is pleased to announce that Juliet E. Compston, M.D., of the University of Cambridge School of Clinical Medicine has been appointed the fifth Editor-in-Chief of the Journal of Bone and Mineral Research (JBMR), the Society’s official journal and the leading journal in the field.

Dr. Compston was selected after a six-month search led by Dr. Philip Osdoby, chairperson of the ASBMR Publications Committee, and an 11-member international search committee representing all aspects of the bone field. She will succeed Dr. Thomas L. Clemens of Johns Hopkins University when his term as Editor-in-Chief ends on December 31, 2012.

Additional information is available on the ASBMR web site.


Two New Virtual Issues: JBMR Classics and Top 10 Downloads

Published on May 3, 2012 ASBMR

The Editor-in-Chief is pleased to announce two new Virtual Issues, JBMR Classics and the Top 10 Most Downloaded articles.

JBMR Classics are the 10 most frequently cited JBMR articles from 1986-present. The Top 10 Downloads Virtual Issue is composed of the JBMR articles that were most frequently downloaded from 2010-2011.

Virtual Issues are thematic or topical collections of JBMR articles. These two new Virtual Issues join those on Basic and Clinical review articles published over the past four years in the JBMR and another on Basic and Clinical Articles on Parathyroid Hormone.
 


Special Chinese Language Issue Now Available Online

Published on Mar 13, 2012 ASBMR

The Editor-in-Chief is pleased to announce the publication of two special Chinese-language issues of the JBMR.

The first special issue, which was published in print in October 2011, is composed of previously published JBMR articles selected by Xu Ling, MD, MPH, of Peking Union Medical College Hospital. This issue is now available online.

A second special issue is under development, with publication expected in April 2012. Future Chinese language issues will also be posted online.

The special Chinese language issues of the JBMR were supported by an educational grant from Eli Lilly-Asia.

Click Here for Access
 


New Virtual Issue on PTH & Basic and Clinical Virtual Issues Updated

Published on Feb 3, 2012 ASBMR

The Editor-in-Chief is pleased to announce a new virtual issue of the JBMR, on the topic of parathyroid hormone (PTH).

This new virtual issue is a collection of PTH papers, both basic research and clinical, published in the JBMR over the past two years. In addition, the virtual issues composed of basic research and clinical Perspectives have both been updated through 2011. To see these and other JBMR virtual issues, click here.
 

 

SEARCH

SEARCH BY CITATION